At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 51 enrolled
Drug / intervention
Extended Release Naltrexone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
In Brief
A Phase 3 clinical trial evaluating Extended Release Naltrexone and Treatment As usual for Opioid Use Disorder and Alcohol Use Disorder. Completed, enrolled 51 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol use disorders.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use Disorder, Alcohol Use Disorder
CountriesCanada, United States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartJun 2014
Primary CompletionMar 2015
TodayJul 2026
First PostedJul 25, 2013
Enrollment StartJun 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.9 years ago
Interventions
Extended Release Naltrexonedrug
Treatment As usualother